Top

Published in:

01-04-2012 | Immunology in Serbia

Single nucleotide polymorphisms in multiple sclerosis: disease susceptibility and treatment response biomarkers

Authors: Vera Pravica, Dusan Popadic, Emina Savic, Milos Markovic, Jelena Drulovic, Marija Mostarica-Stojkovic

Published in: Immunologic Research | Issue 1-2/2012

Abstract

Multiple sclerosis (MS) is a chronic inflammatory demyelinating and neurodegenerative disease of the central nervous system characterized by unpredictable and variable clinical course. Etiology of MS involves both genetic and environmental factors. New technologies identified genetic polymorphisms associated with MS susceptibility among which immunologically relevant genes are significantly overrepresented. Although individual genes contribute only a small part to MS susceptibility, they might be used as biomarkers, thus helping to identify accurate diagnosis, predict clinical disease course and response to therapy. This review focuses on recent progress in research on MS genetics with special emphasis on the possibility to use single nucleotide polymorphism of candidate genes as biomarkers of susceptibility to disease and response to therapy.

Pugliatti M, Rosati G, Carton H, Riise T, Drulovic J, Vecsei L, Milanov I. The epidemiology of multiple sclerosis in Europe. Eur J Neurol. 2006;13:700–22.PubMed

Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 2000;343:938–52.PubMed

International Multiple Sclerosis Genetics Consortium. Wellcome Trust Case Control Consortium 2. Nature. 2011;476:214–9.

Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol. 2007;61:288–99.PubMed

Pekmezovic T, Drulovic J, Milenkovic M, Jarebinski M, Stojsavljevic N, Mesaros S, Kisic D, Kostic J. Lifestyle factors and multiple sclerosis: a case-control study in Belgrade. Neuroepidemiology. 2006;27:212–6.PubMed

Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA. 2006;296:2832–8.PubMed

Kampman MT, Wilsgaard T, Mellgren SI. Outdoor activities and diet in childhood and adolescence relate to MS risk above the Arctic Circle. J Neurol. 2007;254:471–7.PubMed

Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000;47:707–17.PubMed

Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996;46:907–11.PubMed

10.

Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372:1502–17.PubMed

11.

Rio J, Nos C, Tintore M, Tellez N, Galan I, Pelayo R, Comabella M, Montalban X. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol. 2006;59:344–52.PubMed

12.

Miller A, Avidan N, Tzunz-Henig N, Glass-Marmor L, Lejbkowicz I, Pinter RY, Paperna T. Translation towards personalized medicine in multiple sclerosis. J Neurol Sci. 2008;274:68–75.PubMed

13.

Levic ZM, Dujmovic I, Pekmezovic T, Jarebinski M, Marinkovic J, Stojsavljevic N, Drulovic J. Prognostic factors for survival in multiple sclerosis. Mult Scler. 1999;5:171–8.PubMed

14.

Ebers G. Disease evolution in multiple sclerosis. J Neurol. 2006;253:vi3–8.

15.

Fisniku LK, Brex PA, Altmann DR, Miszkiel KA, Benton CE, Lanyon R, Thompson AJ, Miller DH. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain. 2008;131:808–17.PubMed

16.

Miller D, Barkhof F, Montalban X, Thompson A, Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis, part 2: non-conventional MRI, recovery processes, and management. Lancet Neurol. 2005;4:341–8.PubMed

17.

Goverman J, Autoimmune T. cell responses in the central nervous system. Nat Rev Immunol. 2009;9:393–407.PubMed

18.

Fletcher JM, Lalor SJ, Sweeney CM, Tubridy N, Mills KH. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Exp Immunol. 2010;162:1–11.PubMed

19.

Montes M, Zhang X, Berthelot L, Laplaud DA, Brouard S, Jin J, Rogan S, Armao D, Jewells V, Soulillou JP, Markovic-Plese S. Oligoclonal myelin-reactive T-cell infiltrates derived from multiple sclerosis lesions are enriched in Th17 cells. Clin Immunol. 2009;130:133–44.PubMed

20.

Tzartos JS, Friese MA, Craner MJ, Palace J, Newcombe J, Esiri MM, Fugger L. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol. 2008;172:146–55.PubMed

21.

Durelli L, Conti L, Clerico M, Boselli D, Contessa G, Ripellino P, Ferrero B, Eid P, Novelli F. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. Ann Neurol. 2009;65:499–509.PubMed

22.

Kebir H, Kreymborg K, Ifergan I, Dodelet-Devillers A, Cayrol R, Bernard M, Giuliani F, Arbour N, Becher B, Prat A. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med. 2007;13:1173–5.PubMed

23.

Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, Langer-Gould A, Strober S, Cannella B, Allard J, Klonowski P, Austin A, Lad N, Kaminski N, Galli SJ, Oksenberg JR, Raine CS, Heller R, Steinman L. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med. 2002;8:500–8.PubMed

24.

Matusevicius D, Kivisakk P, He B, Kostulas N, Ozenci V, Fredrikson S, Link H. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler. 1999;5:101–4.PubMed

25.

Frisullo G, Nociti V, Iorio R, Patanella AK, Marti A, Caggiula M, Mirabella M, Tonali PA, Batocchi AP. IL17 and IFNgamma production by peripheral blood mononuclear cells from clinically isolated syndrome to secondary progressive multiple sclerosis. Cytokine. 2008;44:22–5.PubMed

26.

Friese MA, Fugger L. Pathogenic CD8(+) T cells in multiple sclerosis. Ann Neurol. 2009;66:132–41.PubMed

27.

Venken K, Hellings N, Liblau R, Stinissen P. Disturbed regulatory T cell homeostasis in multiple sclerosis. Trends Mol Med. 2010;16:58–68.PubMed

28.

Blink SE, Miller SD. The contribution of gammadelta T cells to the pathogenesis of EAE and MS. Curr Mol Med. 2009;9:15–22.PubMed

29.

Berzins SP, Smyth MJ, Baxter AG. Presumed guilty: natural killer T cell defects and human disease. Nat Rev Immunol. 2011;11:131–42.PubMed

30.

Hirotani M, Niino M, Sasaki H. The role of B cells in multiple sclerosis: implications for B-cell-targeted therapy. Curr Med Chem. 2010;17:3215–22.PubMed

31.

Egg R, Reindl M, Deisenhammer F, Linington C, Berger T. Anti-MOG and anti-MBP antibody subclasses in multiple sclerosis. Mult Scler. 2001;7:285–9.PubMed

32.

Markovic M, Trajkovic V, Drulovic J, Mesaros S, Stojsavljevic N, Dujmovic I. Mostarica Stojkovic M. Antibodies against myelin oligodendrocyte glycoprotein in the cerebrospinal fluid of multiple sclerosis patients. J Neurol Sci. 2003;211:67–73.PubMed

33.

Di Pauli F, Mader S, Rostasy K, Schanda K, Bajer-Kornek B, Ehling R, Deisenhammer F, Reindl M, Berger T. Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases. Clin Immunol. 2011;138:247–54.PubMed

34.

Kuhle J, Pohl C, Mehling M, Edan G, Freedman MS, Hartung HP, Polman CH, Miller DH, Montalban X, Barkhof F, Bauer L, Dahms S, Lindberg R, Kappos L, Sandbrink R. Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med. 2007;356:371–8.PubMed

35.

Ray A, Mann MK, Basu S, Dittel BN. A case for regulatory B cells in controlling the severity of autoimmune-mediated inflammation in experimental autoimmune encephalomyelitis and multiple sclerosis. J Neuroimmunol. 2011;230:1–9.PubMed

36.

Gandhi R, Laroni A, Weiner HL. Role of the innate immune system in the pathogenesis of multiple sclerosis. J Neuroimmunol. 2010;221:7–14.PubMed

37.

Težak Ž, Kondratovich MV, Mansfield E. US FDA and personalized medicine: in vitro diagnostic regulatory perspective. Pers Med. 2010;7:517–30.

38.

Alcina A, Fedetz M, Ndagire D, Fernandez O, Leyva L, Guerrero M, Abad-Grau MM, Arnal C, Delgado C, Lucas M, Izquierdo G, Matesanz F. IL2RA/CD25 gene polymorphisms: uneven association with multiple sclerosis (MS) and type 1 diabetes (T1D). PLoS One. 2009;4:e4137.PubMed

39.

Blanco-Kelly F, Matesanz F, Alcina A, Teruel M, Diaz-Gallo LM, Gomez-Garcia M, Lopez-Nevot MA, Rodrigo L, Nieto A, Cardena C, Alcain G, Diaz-Rubio M, de la Concha EG, Fernandez O, Arroyo R, Martin J, Urcelay E. CD40: novel association with Crohn’s disease and replication in multiple sclerosis susceptibility. PLoS One. 2010;5:e11520.PubMed

40.

Zoledziewska M, Costa G, Pitzalis M, Cocco E, Melis C, Moi L, Zavattari P, Murru R, Lampis R, Morelli L, Poddie F, Frongia P, Pusceddu P, Bajorek M, Marras A, Satta AM, Chessa A, Pugliatti M, Sotgiu S, Whalen MB, Rosati G, Cucca F, Marrosu MG. Variation within the CLEC16A gene shows consistent disease association with both multiple sclerosis and type 1 diabetes in Sardinia. Genes Immun. 2009;10:15–7.PubMed

41.

Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447:661–78.

42.

Le Gall I, Chausse AM, Marcadet A, Millasseau P, Beaud’Huy-Lancelin D, Font MP, Paul P, Sayagh B, Masse M, Massart C, et al. New methods for detection of HLA genes polymorphism useful for associated diseases studies. Pathol Biol (Paris). 1986;34:801–7.

43.

Olerup O, Hillert J, Fredrikson S, Olsson T, Kam-Hansen S, Moller E, Carlsson B, Wallin J. Primarily chronic progressive and relapsing/remitting multiple sclerosis: two immunogenetically distinct disease entities. Proc Natl Acad Sci USA. 1989;86:7113–7.PubMed

44.

Haegert DG, Michaud M, Schwab C, Francis GS. Multiple sclerosis and HLA class II susceptibility and resistance genes. J Neurosci Res. 1990;26:66–73.PubMed

45.

Robinson MA, Kindt TJ. Linkage between T cell receptor genes and susceptibility to multiple sclerosis: a complex issue. Reg Immunol. 1992;4:274–83.PubMed

46.

Vandevyver C, Raus P, Stinissen P, Philippaerts L, Cassiman JJ, Raus J. Polymorphism of the tumour necrosis factor beta gene in multiple sclerosis and rheumatoid arthritis. Eur J Immunogenet. 1994;21:377–82.PubMed

47.

Huizinga TW, Westendorp RG, Bollen EL, Keijsers V, Brinkman BM, Langermans JA, Breedveld FC, Verweij CL, van de Gaer L, Dams L, Crusius JB, Garcia-Gonzalez A, van Oosten BW, Polman CH, Pena AS. TNF-alpha promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients. J Neuroimmunol. 1997;72:149–53.PubMed

48.

Vandenbroeck K, Martino G, Marrosu M, Consiglio A, Zaffaroni M, Vaccargiu S, Franciotta D, Ruggeri M, Comi G, Grimaldi LM. Occurrence and clinical relevance of an interleukin-4 gene polymorphism in patients with multiple sclerosis. J Neuroimmunol. 1997;76:189–92.PubMed

49.

Ligers A, Xu C, Saarinen S, Hillert J, Olerup O. The CTLA-4 gene is associated with multiple sclerosis. J Neuroimmunol. 1999;97:182–90.PubMed

50.

Hoffjan S, Nicolae D, Ober C. Association studies for asthma and atopic diseases: a comprehensive review of the literature. Respir Res. 2003;4:14.PubMed

51.

Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, Collins FS, Manolio TA. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci USA. 2009;106:9362–7.PubMed

52.

Hafler DA, Compston A, Sawcer S, Lander ES, Daly MJ, De Jager PL, de Bakker PI, Gabriel SB, Mirel DB, Ivinson AJ, Pericak-Vance MA, Gregory SG, Rioux JD, McCauley JL, Haines JL, Barcellos LF, Cree B, Oksenberg JR, Hauser SL. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med. 2007;357:851–62.PubMed

53.

Australia and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene). Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat Genet. 2009;41:824–8.

54.

Baranzini SE, Wang J, Gibson RA, Galwey N, Naegelin Y, Barkhof F, Radue EW, Lindberg RL, Uitdehaag BM, Johnson MR, Angelakopoulou A, Hall L, Richardson JC, Prinjha RK, Gass A, Geurts JJ, Kragt J, Sombekke M, Vrenken H, Qualley P, Lincoln RR, Gomez R, Caillier SJ, George MF, Mousavi H, Guerrero R, Okuda DT, Cree BA, Green AJ, Waubant E, Goodin DS, Pelletier D, Matthews PM, Hauser SL, Kappos L, Polman CH, Oksenberg JR. Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet. 2009;18:767–78.PubMed

55.

Johnson BA, Wang J, Taylor EM, Caillier SJ, Herbert J, Khan OA, Cross AH, De Jager PL, Gourraud PA, Cree BC, Hauser SL, Oksenberg JR. Multiple sclerosis susceptibility alleles in African Americans. Genes Immun. 2010;11:343–50.PubMed

56.

De Jager PL, Jia X, Wang J, de Bakker PI, Ottoboni L, Aggarwal NT, Piccio L, Raychaudhuri S, Tran D, Aubin C, Briskin R, Romano S, Baranzini SE, McCauley JL, Pericak-Vance MA, Haines JL, Gibson RA, Naeglin Y, Uitdehaag B, Matthews PM, Kappos L, Polman C, McArdle WL, Strachan DP, Evans D, Cross AH, Daly MJ, Compston A, Sawcer SJ, Weiner HL, Hauser SL, Hafler DA, Oksenberg JR. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet. 2009;41:776–82.PubMed

57.

Rubio JP, Stankovich J, Field J, Tubridy N, Marriott M, Chapman C, Bahlo M, Perera D, Johnson LJ, Tait BD, Varney MD, Speed TP, Taylor BV, Foote SJ, Butzkueven H, Kilpatrick TJ. Replication of KIAA0350, IL2RA, RPL5 and CD58 as multiple sclerosis susceptibility genes in Australians. Genes Immun. 2008;9:624–30.PubMed

58.

Pandit L, Ban M, Sawcer S, Singhal B, Nair S, Radhakrishnan K, Shetty R, Misri Z, Hegde S, Bhat IG. Evaluation of the established non-MHC multiple sclerosis loci in an Indian population. Mult Scler (Houndmills, Basingstoke, England) 2011;17:139–43.

59.

Jakkula E, Leppa V, Sulonen AM, Varilo T, Kallio S, Kemppinen A, Purcell S, Koivisto K, Tienari P, Sumelahti ML, Elovaara I, Pirttila T, Reunanen M, Aromaa A, Oturai AB, Sondergaard HB, Harbo HF, Mero IL, Gabriel SB, Mirel DB, Hauser SL, Kappos L, Polman C, De Jager PL, Hafler DA, Daly MJ, Palotie A, Saarela J, Peltonen L. Genome-wide association study in a high-risk isolate for multiple sclerosis reveals associated variants in STAT3 gene. Am J Hum Genet. 2010;86:285–91.PubMed

60.

International Multiple Sclerosis Genetics Consortium. The genetic association of variants in CD6, TNFRSF1A and IRF8 to multiple sclerosis: a multicenter case-control study. PLoS One 2011;6:e18813.

61.

Lill CM RJ, McQueen MB, Bagade S, Schjeide BM, Zipp F, Bertram L. The MSGene database. Alzheimer Research Forum.

62.

Weber F, Fontaine B, Cournu-Rebeix I, Kroner A, Knop M, Lutz S, Muller-Sarnowski F, Uhr M, Bettecken T, Kohli M, Ripke S, Ising M, Rieckmann P, Brassat D, Semana G, Babron MC, Mrejen S, Gout C, Lyon-Caen O, Yaouanq J, Edan G, Clanet M, Holsboer F, Clerget-Darpoux F, Muller-Myhsok B. IL2RA and IL7RA genes confer susceptibility for multiple sclerosis in two independent European populations. Genes Immun. 2008;9:259–63.PubMed

63.

Akkad DA, Hoffjan S, Petrasch-Parwez E, Beygo J, Gold R, Epplen JT. Variation in the IL7RA and IL2RA genes in German multiple sclerosis patients. J Autoimmun. 2009;32:110–5.PubMed

64.

Gregory SG, Schmidt S, Seth P, Oksenberg JR, Hart J, Prokop A, Caillier SJ, Ban M, Goris A, Barcellos LF, Lincoln R, McCauley JL, Sawcer SJ, Compston DA, Dubois B, Hauser SL, Garcia-Blanco MA, Pericak-Vance MA, Haines JL. Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat Genet. 2007;39:1083–91.PubMed

65.

McElroy JP, Oksenberg JR. Multiple sclerosis genetics 2010. Neurol Clin. 2011;29:219–31.PubMed

66.

Lundmark F, Duvefelt K, Iacobaeus E, Kockum I, Wallstrom E, Khademi M, Oturai A, Ryder LP, Saarela J, Harbo HF, Celius EG, Salter H, Olsson T, Hillert J. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat Genet. 2007;39:1108–13.PubMed

67.

Jensen CJ, Stankovich J, Van der Walt A, Bahlo M, Taylor BV, van der Mei IA, Foote SJ, Kilpatrick TJ, Johnson LJ, Wilkins E, Field J, Danoy P, Brown MA, Rubio JP, Butzkueven H. Multiple sclerosis susceptibility-associated SNPs do not influence disease severity measures in a cohort of Australian MS patients. PLoS One. 2010;5:e10003.PubMed

68.

Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA. 1997;94:3195–9.PubMed

69.

Wirz SA, Morale MC, Marchetti B, Barr AM, Sotgiu S, Rosati G, Pugliatti M, Sanna MV, Giliberto O, Bartfai T, Conti B. High frequency of TNF alleles −238A and −376A in individuals from northern Sardinia. Cytokine. 2004;26:149–54.PubMed

70.

Kauffman MA, Moron DG, Sandoval G, Sica RE, Garcea O, Villa AM. Is tumor necrosis factor-376A promoter polymorphism associated with susceptibility to multiple sclerosis? Medicina. 2007;67:436–8.PubMed

71.

Losonczi E, Bencsik K, Nagy ZF, Honti V, Szalczer E, Rajda C, Illes Z, Matyas K, Rozsa C, Csepany T, Fuvesi J, Vecsei L. Tumour necrosis factor alpha gene (TNF-alpha)-376 polymorphism in Hungarian patients with primary progressive multiple sclerosis. J Nneuroimmunol. 2009;208:115–8.

72.

Martinez A, Rubio A, Urcelay E, Fernandez-Arquero M, De Las Heras V, Arroyo R, Villoslada P, Montalban X, De La Concha EG. TNF-376A marks susceptibility to MS in the Spanish population: a replication study. Neurology. 2004;62:809–10.PubMed

73.

Akcali A, Pehlivan S, Pehlivan M, Sever T, Akgul P, Neyal M. TNF-alpha promoter polymorphisms in multiple sclerosis: no association with −308 and −238 alleles, but the −857 alleles in associated with the disease in Turkish patients. Int J Immunogenet. 2010;37:91–5.PubMed

74.

Perrey C, Turner SJ, Pravica V, Howell WM, Hutchinson IV. ARMS-PCR methodologies to determine IL-10, TNF-alpha, TNF-beta and TGF-beta 1 gene polymorphisms. Transpl Immunol. 1999;7:127–8.PubMed

75.

Drulovic J, Popadic D, Mesaros S, Dujmovic I, Cvetkovic I, Miljkovic D, Stojsavljevic N, Pravica V, Pekmezovic T, Bogdanovic G, Jarebinski M, Mostarica Stojkovic M. Decreased frequency of the tumor necrosis factor alpha −308 allele in Serbian patients with multiple sclerosis. Eur Neurol. 2003;50:25–9.PubMed

76.

Veugelers M, Vermeesch J, Reekmans G, Steinfeld R, Marynen P, David G. Characterization of glypican-5 and chromosomal localization of human GPC5, a new member of the glypican gene family. Genomics. 1997;40:24–30.PubMed

77.

Luxardi G, Galli A, Forlani S, Lawson K, Maina F, Dono R. Glypicans are differentially expressed during patterning and neurogenesis of early mouse brain. Biochem Biophys Res Commun. 2007;352:55–60.PubMed

78.

Cavanillas ML, Fernandez O, Comabella M, Alcina A, Fedetz M, Izquierdo G, Lucas M, Cenit MC, Arroyo R, Vandenbroeck K, Alloza I, Garcia-Barcina M, Antiguedad A, Leyva L, Gomez CL, Olascoaga J, Otaegui D, Blanco Y, Saiz A, Montalban X, Matesanz F, Urcelay E. Replication of top markers of a genome-wide association study in multiple sclerosis in Spain. Genes Immun. 2011;12:110–5.PubMed

79.

Li Y, Sheu CC, Ye Y, de Andrade M, Wang L, Chang SC, Aubry MC, Aakre JA, Allen MS, Chen F, Cunningham JM, Deschamps C, Jiang R, Lin J, Marks RS, Pankratz VS, Su L, Sun Z, Tang H, Vasmatzis G, Harris CC, Spitz MR, Jen J, Wang R, Zhang ZF, Christiani DC, Wu X, Yang P. Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncol. 2010;11:321–30.PubMed

80.

Peters AL, Plenge RM, Graham RR, Altshuler DM, Moser KL, Gaffney PM, Bishop GA. A novel polymorphism of the human CD40 receptor with enhanced function. Blood. 2008;112:1863–71.PubMed

81.

Buck D, Kroner A, Rieckmann P, Maurer M, Wiendl H. Analysis of the C/T(-1) single nucleotide polymorphism in the CD40 gene in multiple sclerosis. Tissue Antigens. 2006;68:335–8.PubMed

82.

Duddy M, Haghikia A, Cocco E, Eggers C, Drulovic J, Carmona O, Zephir H, Gold R. Managing MS in a changing treatment landscape. J Neurol. 2011;258:728–39.PubMed

83.

Dhib-Jalbut S, Marks S. Interferon-beta mechanisms of action in multiple sclerosis. Neurology. 2010;74(Suppl 1):S17–24.PubMed

84.

Polman CH, Bertolotto A, Deisenhammer F, Giovannoni G, Hartung HP, Hemmer B, Killestein J, McFarland HF, Oger J, Pachner AR, Petkau J, Reder AT, Reingold SC, Schellekens H, Sorensen PS. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol. 2010;9:740–50.PubMed

85.

Alvarez-Lafuente R, Blanco-Kelly F, Garcia-Montojo M, Martinez A, De Las Heras V, Dominguez-Mozo MI, Bartolome M, Garcia-Martinez A, De la Concha EG, Urcelay E, Arroyo R. CD46 in a Spanish cohort of multiple sclerosis patients: genetics, mRNA expression and response to interferon-beta treatment. Mult Scler. 2011;17:513–20.PubMed

86.

Drulovic J, Savic E, Pekmezovic T, Mesaros S, Stojsavljevic N, Dujmovic-Basuroski I, Kostic J, Vasic V, Mostarica Stojkovic M, Popadic D. Expression of Th1 and Th17 cytokines and transcription factors in multiple sclerosis patients: does baseline T-bet mRNA predict the response to interferon-beta treatment? J Neuroimmunol. 2009;215:90–5.PubMed

87.

Byun E, Caillier SJ, Montalban X, Villoslada P, Fernandez O, Brassat D, Comabella M, Wang J, Barcellos LF, Baranzini SE, Oksenberg JR. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Arch Neurol. 2008;65:337–44.PubMed

88.

Cenit MD, Blanco-Kelly F, de las Heras V, Bartolome M, de la Concha EG, Urcelay E, Arroyo R, Martinez A. Glypican 5 is an interferon-beta response gene: a replication study. Mult Scle (Houndmills, Basingstoke, England) 2009;15:913–7.

89.

Chernousov MA, Rothblum K, Stahl RC, Evans A, Prentiss L, Carey DJ. Glypican-1 and alpha4(V) collagen are required for Schwann cell myelination. J Neurosci. 2006;26:508–17.PubMed

90.

Lee JS, Chien CB. When sugars guide axons: insights from heparan sulphate proteoglycan mutants. Nat Rev Genet. 2004;5:923–35.PubMed

91.

Van Vactor D, Wall DP, Johnson KG. Heparan sulfate proteoglycans and the emergence of neuronal connectivity. Curr Opin Neurobiol. 2006;16:40–51.PubMed

92.

Worapamorn W, Haase HR, Li H, Bartold PM. Growth factors and cytokines modulate gene expression of cell-surface proteoglycans in human periodontal ligament cells. J Cell Physiol. 2001;186:448–56.PubMed

93.

Leyva L, Fernandez O, Fedetz M, Blanco E, Fernandez VE, Oliver B, Leon A, Pinto-Medel MJ, Mayorga C, Guerrero M, Luque G, Alcina A, Matesanz F. IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response. J Neuroimmunol. 2005;163:165–71.PubMed

94.

O’Doherty C, Favorov A, Heggarty S, Graham C, Favorova O, Ochs M, Hawkins S, Hutchinson M, O’Rourke K, Vandenbroeck K. Genetic polymorphisms, their allele combinations and IFN-beta treatment response in Irish multiple sclerosis patients. Pharmacogenomics. 2009;10:1177–86.PubMed

95.

Hoffmann S, Cepok S, Grummel V, Lehmann-Horn K, Hackermuller J, Stadler PF, Hartung HP, Berthele A, Deisenhammer F, Wassmuth R, Hemmer B. HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis. Am J Hum Genet. 2008;83:219–27.PubMed

96.

Weber F, Cepok S, Wolf C, Berthele A, Uhr M, Bettecken T, Buck D, Hartung HP, Holsboer F, Muller-Myhsok B, Hemmer B. Single-nucleotide polymorphisms in HLA- and non-HLA genes associated with the development of antibodies to interferon-beta therapy in multiple sclerosis patients. Pharmacogenomics J. 2011. doi:10.1038/tpj.2011.14.

97.

Martinez A, de las Heras V, Mas Fontao A, Bartolome M, de la Concha EG, Urcelay E, Arroyo R. An IFNG polymorphism is associated with interferon-beta response in Spanish MS patients. J Neuroimmunol. 2006;173:196–9.PubMed

98.

Pravica V, Perrey C, Stevens A, Lee JH, Hutchinson IV. A single nucleotide polymorphism in the first intron of the human IFN-gamma gene: absolute correlation with a polymorphic CA microsatellite marker of high IFN-gamma production. Hum Immunol. 2000;61:863–6.PubMed

99.

Enevold C, Oturai AB, Sorensen PS, Ryder LP, Koch-Henriksen N, Bendtzen K. Polymorphisms of innate pattern recognition receptors, response to interferon-beta and development of neutralizing antibodies in multiple sclerosis patients. Mult Scler. 2010;16:942–9.PubMed

100.

Mirowska-Guzel D, Gromadzka G, Mach A, Czlonkowski A, Czlonkowska A. Association of IL1A, IL1B, ILRN, IL6, IL10 and TNF-alpha polymorphisms with risk and clinical course of multiple sclerosis in a Polish population. J Neuroimmunol. 2011;236:87–92.PubMed

101.

Sarial S, Shokrgozar MA, Amirzargar A, Shokri F, Radfar J, Zohrevand P, Arjang Z, Sahraian MA, Lotfi J. IL-1, IL-1R and TNFalpha gene polymorphisms in Iranian patients with multiple sclerosis. Iran J Allergy Asthma Immunol. 2008;7:37–40.PubMed

102.

Ristic S, Lovrecic L, Starcevic-Cizmarevic N, Brajenovic-Milic B, Sega Jazbec S, Sepcic J, Kapovic M, Peterlin B. Tumor necrosis factor-alpha-308 gene polymorphism in Croatian and Slovenian multiple sclerosis patients. Eur Neurol. 2007;57:203–7.PubMed

103.

Mihailova S, Ivanova M, Mihaylova A, Quin L, Mikova O, Naumova E. Pro- and anti-inflammatory cytokine gene polymorphism profiles in Bulgarian multiple sclerosis patients. J Neuroimmunol. 2005;168:138–43.PubMed

104.

Handel AE, Handunnetthi L, Berlanga AJ, Watson CT, Morahan JM, Ramagopalan SV. The effect of single nucleotide polymorphisms from genome wide association studies in multiple sclerosis on gene expression. PLoS One. 2010;5:e10142.PubMed

105.

Dendrou CA, Plagnol V, Fung E, Yang JH, Downes K, Cooper JD, Nutland S, Coleman G, Himsworth M, Hardy M, Burren O, Healy B, Walker NM, Koch K, Ouwehand WH, Bradley JR, Wareham NJ, Todd JA, Wicker LS. Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource. Nat Genet. 2009;41:1011–5.PubMed

106.

Maier LM, Lowe CE, Cooper J, Downes K, Anderson DE, Severson C, Clark PM, Healy B, Walker N, Aubin C, Oksenberg JR, Hauser SL, Compston A, Sawcer S, De Jager PL, Wicker LS, Todd JA, Hafler DA. IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor production. PLoS Genet. 2009;5:e1000322.PubMed

107.

Sombekke MH, van der Voort LF, Kragt JJ, Nielsen JM, Guzel H, Visser A, Oudejans CB, Crusius JB, Pena AS, Vrenken H, Polman CH, Killestein J. Relevance of IL7R genotype and mRNA expression in Dutch patients with multiple sclerosis. Mult Scler. 2011;17:922–30.PubMed

108.

Alcina A, Vandenbroeck K, Otaegui D, Saiz A, Gonzalez JR, Fernandez O, Cavanillas ML, Cenit MC, Arroyo R, Alloza I, Garcia-Barcina M, Antiguedad A, Leyva L, Izquierdo G, Lucas M, Fedetz M, Pinto-Medel MJ, Olascoaga J, Blanco Y, Comabella M, Montalban X, Urcelay E, Matesanz F. The autoimmune disease-associated KIF5A, CD226 and SH2B3 gene variants confer susceptibility for multiple sclerosis. Genes Immun. 2010;11:439–45.PubMed

109.

Comabella M, Craig DW, Morcillo-Suarez C, Rio J, Navarro A, Fernandez M, Martin R, Montalban X. Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis. Arch Neurol. 2009;66:972–8.PubMed

110.

Cunningham S, Graham C, Hutchinson M, Droogan A, O’Rourke K, Patterson C, McDonnell G, Hawkins S, Vandenbroeck K. Pharmacogenomics of responsiveness to interferon IFN-beta treatment in multiple sclerosis: a genetic screen of 100 type I interferon-inducible genes. Clin Pharmacol Ther. 2005;78:635–46.PubMed

111.

O’Brien M, Lonergan R, Costelloe L, O’Rourke K, Fletcher JM, Kinsella K, Sweeney C, Antonelli G, Mills KH, O’Farrelly C, Hutchinson M, Tubridy N. OAS1: a multiple sclerosis susceptibility gene that influences disease severity. Neurology. 2010;75:411–8.PubMed

Title: Single nucleotide polymorphisms in multiple sclerosis: disease susceptibility and treatment response biomarkers
Authors: Vera Pravica
Dusan Popadic
Emina Savic
Milos Markovic
Jelena Drulovic
Marija Mostarica-Stojkovic
Publication date: 01-04-2012
Publisher: Springer-Verlag
Published in: Immunologic Research / Issue 1-2/2012
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI: https://doi.org/10.1007/s12026-012-8273-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Single nucleotide polymorphisms in multiple sclerosis: disease susceptibility and treatment response biomarkers

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1-2/2012

The roles of Galectin-3 in autoimmunity and tumor progression

The response of human dendritic cells to co-ligation of pattern-recognition receptors

Functional properties of granulocytes after thermal injury

Immunologic Research: Publishing knowledge of the future today!

Investigation of NK cell function and their modulation in different malignancies

Host immune defense against Aspergillus fumigatus: insight from experimental systemic (disseminated) infection